<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31872946</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2040-1124</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of diabetes investigation</Title>
          <ISOAbbreviation>J Diabetes Investig</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pancreatic stellate cells in the islets as a novel target to preserve the pancreatic β-cell mass and function.</ArticleTitle>
        <Pagination>
          <StartPage>268</StartPage>
          <EndPage>280</EndPage>
          <MedlinePgn>268-280</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jdi.13202</ELocationID>
        <Abstract>
          <AbstractText>There are numerous lines of clinical evidence that inhibition of the renin-angiotensin system (RAS) can prevent and delay the development of diabetes. Also, the role of RAS in the pathogenesis of diabetes, including insulin resistance and β-cell dysfunction, has been extensively investigated. Nevertheless, this role had not yet been fully shown. A variety of possible protective mechanisms for RAS blockers in the regulation of glucose homeostasis have been suggested. However, the direct effect on pancreatic islet fibrosis has only recently been spotlighted. Various degrees of islet fibrosis are often observed in the islets of patients with type 2 diabetes mellitus, which can be associated with a decrease in β-cell mass and function in these patients. Pancreatic stellate cells are thought to be deeply involved in this islet fibrosis. In this process, the activation of RAS in islets is shown to transform quiescent pancreatic stellate cells into the activated form, stimulates their proliferation and consequently leads to islet fibrotic destruction. In this article, we introduce existing clinical and experimental evidence for diabetes prevention through inhibition of RAS, and review the responsible local RAS signaling pathways in pancreatic stellate cells. Finally, we propose possible targets for the prevention of islet fibrosis.</AbstractText>
          <CopyrightInformation>© 2019 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Yeoree</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Ji-Won</ForeName>
            <Initials>JW</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Heon-Seok</ForeName>
            <Initials>HS</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Eun-Young</ForeName>
            <Initials>EY</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoon</LastName>
            <ForeName>Kun-Ho</ForeName>
            <Initials>KH</Initials>
            <Identifier Source="ORCID">0000-0002-9109-2208</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>01</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Diabetes Investig</MedlineTA>
        <NlmUniqueID>101520702</NlmUniqueID>
        <ISSNLinking>2040-1116</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050417" MajorTopicYN="N">Insulin-Secreting Cells</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007515" MajorTopicYN="N">Islets of Langerhans</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058954" MajorTopicYN="N">Pancreatic Stellate Cells</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012084" MajorTopicYN="Y">Renin-Angiotensin System</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Islet fibrosis</Keyword>
        <Keyword MajorTopicYN="N">Pancreatic stellate cells</Keyword>
        <Keyword MajorTopicYN="N">Renin-angiotensin system</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31872946</ArticleId>
        <ArticleId IdType="pmc">PMC7078117</ArticleId>
        <ArticleId IdType="doi">10.1111/jdi.13202</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes
1988; 37: 1595‐1607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3056758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Group UKPDS
. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes
1995; 44: 1249–1258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7589820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Levy J, Atkinson AB, Bell PM, et al
Beta‐cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10‐year follow‐up of the Belfast Diet Study. Diabet Med
1998; 15: 290–296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9585393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Butler AE, Janson J, Bonner‐Weir S, et al
Beta‐cell deficit and increased beta‐cell apoptosis in humans with type 2 diabetes. Diabetes
2003; 52: 102–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12502499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yoon KH, Ko SH, Cho JH, et al
Selective beta‐cell loss and alpha‐cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab
2003; 88: 2300–2308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12727989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Weyer C, Bogardus C, Mott DM, et al
The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Investig
1999; 104: 787–794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC408438</ArticleId>
            <ArticleId IdType="pubmed">10491414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes
2009; 58: 773–795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2661582</ArticleId>
            <ArticleId IdType="pubmed">19336687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Investig
2006; 116: 1802–1812.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1483155</ArticleId>
            <ArticleId IdType="pubmed">16823478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yoon KH, Lee JH, Kim JW, et al
Epidemic obesity and type 2 diabetes in Asia. Lancet
2006; 368: 1681–1688.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17098087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chan JC, Malik V, Jia W, et al
Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA
2009; 301: 2129–2140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19470990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta‐cell dysfunction. Endocr Rev
2008; 29: 351–366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2528858</ArticleId>
            <ArticleId IdType="pubmed">18048763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jurgens CA, Toukatly MN, Fligner CL, et al
Beta‐cell loss and beta‐cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol
2011; 178: 2632–2640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3123989</ArticleId>
            <ArticleId IdType="pubmed">21641386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Keating ST, El‐Osta A. Epigenetic changes in diabetes. Clin Genet
2013; 84: 1–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23398084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Weir GC, Bonner‐Weir S. Five stages of evolving beta‐cell dysfunction during progression to diabetes. Diabetes
2004; 53(Suppl 3): S16–S21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15561905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim JW, Ko SH, Cho JH, et al
Loss of beta‐cells with fibrotic islet destruction in type 2 diabetes mellitus. Front Biosci
2008; 13: 6022–6033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18508639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Investig
2007; 117: 524–529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1804380</ArticleId>
            <ArticleId IdType="pubmed">17332879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Omary MB, Lugea A, Lowe AW, et al
The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Investig
2007; 117: 50–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1716214</ArticleId>
            <ArticleId IdType="pubmed">17200706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Apte MV, Haber PS, Darby SJ, et al
Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut
1999; 44: 534–541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1727467</ArticleId>
            <ArticleId IdType="pubmed">10075961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Homo‐Delarche F, Calderari S, Irminger JC, et al
Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes
2006; 55: 1625–1633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16731824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ko SH, Kwon HS, Kim SR, et al
Ramipril treatment suppresses islet fibrosis in Otsuka Long‐Evans Tokushima fatty rats. Biochem Biophys Res Commun
2004; 316: 114–122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15003519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cho JH, Kim JW, Shin JA, et al
Beta‐cell mass in people with type 2 diabetes. J Diabetes Investig
2011; 2: 6–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4008010</ArticleId>
            <ArticleId IdType="pubmed">24843456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ko SH, Hong OK, Kim JW, et al
High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin‐angiotensin system. J Cell Biochem
2006; 98: 343–355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16408293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
le Roux CW, Astrup A, Fujioka K, et al
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet
2017; 389: 1399–1409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28237263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Torgerson JS, Hauptman J, Boldrin MN, et al
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care
2004; 27: 155–161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14693982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta‐blocking agents?
Am J Hypertens
1998; 11: 1258–1265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9799045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hansson L, Lindholm LH, Niskanen L, et al
Effect of angiotensin‐converting‐enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet
1999; 353: 611–616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10030325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yusuf S, Sleight P, Pogue J, et al
Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. N Engl J Med
2000; 342: 145–153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10639539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial
. Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA
2002; 288: 2981–2997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12479763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barzilay JI, Davis BR, Cutler JA, et al
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med
2006; 166: 2191–2201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17101936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lindholm LH, Ibsen H, Borch‐Johnsen K, et al
Risk of new‐onset diabetes in the Losartan intervention for endpoint reduction in hypertension study. J Hypertens
2002; 20: 1879–1886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12195132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lithell H, Hansson L, Skoog I, et al
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double‐blind intervention trial. J Hypertens
2003; 21: 875–886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12714861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kjeldsen SE, Julius S, Mancia G, et al
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high‐risk hypertensive patients: the VALUE trial. J Hypertens
2006; 24: 1405–1412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16794491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bosch J, Yusuf S, Gerstein HC, et al
Effect of ramipril on the incidence of diabetes. N Engl J Med
2006; 355: 1551–1562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16980380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
NAVIGATOR Study Group
, McMurray JJ, Holman RR, et al
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med
2010; 362: 1477–1490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20228403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Geng DF, Jin DM, Wu W, et al
Angiotensin receptor blockers for prevention of new‐onset type 2 diabetes: a meta‐analysis of 59,862 patients. Int J Cardiol
2012; 155: 236–242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21036409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Geng DF, Jin DM, Wu W, et al
Angiotensin converting enzyme inhibitors for prevention of new‐onset type 2 diabetes mellitus: a meta‐analysis of 72,128 patients. Int J Cardiol
2013; 167: 2605–2610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22809536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chu KY, Lau T, Carlsson PO, et al
Angiotensin II type 1 receptor blockade improves beta‐cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes
2006; 55: 367–374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16443769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin‐generating system and dose‐dependent inhibition of glucose‐stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia
2004; 47: 240–248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14722647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Suzuki K, Nakagawa O, Aizawa Y. Improved early‐phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. Clin Exp Hypertens
2008; 30: 309–314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2495588</ArticleId>
            <ArticleId IdType="pubmed">18633754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
van der Zijl NJ, Moors CC, Goossens GH, et al
Valsartan improves {beta}‐cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care
2011; 34: 845–851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3064038</ArticleId>
            <ArticleId IdType="pubmed">21330640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Paolisso G, Tagliamonte MR, Gambardella A, et al
Losartan mediated improvement in insulin action is mainly due to an increase in non‐oxidative glucose metabolism and blood flow in insulin‐resistant hypertensive patients. J Hum Hypertens
1997; 11: 307–312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9205938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Olsen MH, Fossum E, Hoieggen A, et al
Long‐term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens
2005; 23: 891–898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15775796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carvalho CR, Thirone AC, Gontijo JA, et al
Statement of Retraction. Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 1997;46: 1950–1957. Diabetes
2016; 65: 1128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27208026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lupi R, Del Guerra S, Bugliani M, et al
The direct effects of the angiotensin‐converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J Endocrinol
2006; 154: 355–361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16452552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Saitoh Y, Hongwei W, Ueno H, et al
Telmisartan attenuates fatty‐acid‐induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta‐cells. Diabetes Metab
2009; 35: 392–397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19713141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Saitoh Y, Hongwei W, Ueno H, et al
Candesartan attenuates fatty acid‐induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta‐cells. Diabetes Res Clin Pract
2010; 90: 54–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20667613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schupp M, Janke J, Clasen R, et al
Angiotensin type 1 receptor blockers induce peroxisome proliferator‐activated receptor‐gamma activity. Circulation
2004; 109: 2054–2057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15117841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Benson SC, Pershadsingh HA, Ho CI, et al
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma‐modulating activity. Hypertension
2004; 43: 993–1002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15007034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schupp M, Clemenz M, Gineste R, et al
Molecular characterization of new selective peroxisome proliferator‐activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes
2005; 54: 3442–3452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16306360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yvan‐Charvet L, Quignard‐Boulange A. Role of adipose tissue renin‐angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int
2011; 79: 162–168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20944545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tahmasebi M, Puddefoot JR, Inwang ER, et al
The tissue renin‐angiotensin system in human pancreas. J Endocrinol
1999; 161: 317–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10320830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Suzuki Y, Ruiz‐Ortega M, Lorenzo O, et al
Inflammation and angiotensin II. Int J Biochem Cell Biol
2003; 35: 881–900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12676174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Danser AH. Local renin‐angiotensin systems: the unanswered questions. Int J Biochem Cell Biol
2003; 35: 759–768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12676161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Boffa JJ, Lu Y, Placier S, et al
Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol
2003; 14: 1132–1144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12707384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Durante A, Peretto G, Laricchia A, et al
Role of the renin‐angiotensin‐aldosterone system in the pathogenesis of atherosclerosis. Curr Pharm Des
2012; 18: 981–1004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22283771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Engeli S, Gorzelniak K, Kreutz R, et al
Co‐expression of renin‐angiotensin system genes in human adipose tissue. J Hypertens
1999; 17: 555–560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10404958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kawano K, Hirashima T, Mori S, et al
OLETF (Otsuka Long‐Evans Tokushima Fatty) rat: a new NIDDM rat strain. Diabetes Res Clin Pract
1994; 24(Suppl): S317–320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7859627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tikellis C, Wookey PJ, Candido R, et al
Improved islet morphology after blockade of the renin‐ angiotensin system in the ZDF rat. Diabetes
2004; 53: 989–997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15047614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Watari N, Hotta Y, Mabuchi Y. Morphological studies on a vitamin A‐storing cell and its complex with macrophage observed in mouse pancreatic tissues following excess vitamin A administration. Okajimas Folia Anat Jpn
1982; 58: 837–858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7122019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bynigeri RR, Jakkampudi A, Jangala R, et al
Pancreatic stellate cell: Pandora's box for pancreatic disease biology. World J Gastroenterol
2017; 23: 382–405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5291844</ArticleId>
            <ArticleId IdType="pubmed">28210075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bachem MG, Schneider E, Gross H, et al
Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology
1998; 115: 421–432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9679048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Apte MV, Haber PS, Applegate TL, et al
Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut
1998; 43: 128–133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1727174</ArticleId>
            <ArticleId IdType="pubmed">9771417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yoshikawa H, Kihara Y, Taguchi M, et al
Role of TGF‐beta1 in the development of pancreatic fibrosis in Otsuka Long‐Evans Tokushima Fatty rats. Am J Physiol Gastrointest Liver Physiol
2002; 282: G549–G558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11842006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
De Meyts P, Wallach B, Christoffersen CT, et al
The insulin‐like growth factor‐I receptor. Structure, ligand‐binding mechanism and signal transduction. Horm Res
1994; 42: 152–169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7868068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Svegliati‐Baroni G, Ridolfi F, Di Sario A, et al
Insulin and insulin‐like growth factor‐1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology
1999; 29: 1743–1751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10347117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hong OK, Lee SH, Rhee M, et al
Hyperglycemia and hyperinsulinemia have additive effects on activation and proliferation of pancreatic stellate cells: possible explanation of islet‐specific fibrosis in type 2 diabetes mellitus. J Cell Biochem
2007; 101: 665–675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17212361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin‐4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept
2004; 117: 77–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14700743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu G, Stoffers DA, Habener JF, et al
Exendin‐4 stimulates both beta‐cell replication and neogenesis, resulting in increased beta‐cell mass and improved glucose tolerance in diabetic rats. Diabetes
1999; 48: 2270–2276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10580413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chung Kim le T, Hosaka T, Yoshida M, et al
Exendin‐4, a GLP‐1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun
2009; 390: 613–618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19850014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hirata K, Kume S, Araki S, et al
Exendin‐4 has an anti‐hypertensive effect in salt‐sensitive mice model. Biochem Biophys Res Commun
2009; 380: 44–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19150338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li W, Cui M, Wei Y, et al
Inhibition of the expression of TGF‐beta1 and CTGF in human mesangial cells by exendin‐4, a glucagon‐like peptide‐1 receptor agonist. Cell Physiol Biochem
2012; 30: 749–757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22890152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jhala US, Canettieri G, Screaton RA, et al
cAMP promotes pancreatic beta‐cell survival via CREB‐mediated induction of IRS2. Genes Dev
2003; 17: 1575–1580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC196130</ArticleId>
            <ArticleId IdType="pubmed">12842910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim JW, Park SY, You YH, et al
Suppression of ROS production by exendin‐4 in PSC attenuates the high glucose‐induced islet fibrosis. PLoS One
2016; 11: e0163187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5157943</ArticleId>
            <ArticleId IdType="pubmed">27977690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rahmoune H, Thompson PW, Ward JM, et al
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non‐insulin‐dependent diabetes. Diabetes
2005; 54: 3427–3434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16306358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shin SJ, Chung S, Kim SJ, et al
Effect of sodium‐glucose co‐transporter 2 inhibitor, dapagliflozin, on renal renin‐angiotensin system in an animal model of type 2 diabetes. PLoS One
2016; 11: e0165703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5089752</ArticleId>
            <ArticleId IdType="pubmed">27802313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Macdonald FR, Peel JE, Jones HB, et al
The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab
2010; 12: 1004–1012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20880347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Okauchi S, Shimoda M, Obata A, et al
Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic beta‐cells in obese type 2 diabetic db/db mice. Biochem Biophys Res Commun
2016; 470: 772–782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26505796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tham DM, Martin‐McNulty B, Wang YX, et al
Angiotensin II is associated with activation of NF‐kappaB‐mediated genes and downregulation of PPARs. Physiol Genomics
2002; 11: 21–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12361987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shimizu K, Shiratori K, Kobayashi M, et al
Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma‐independent mechanism. Pancreas
2004; 29: 67–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15211114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee YE, Kim JW, Lee EM, et al
Chronic resveratrol treatment protects pancreatic islets against oxidative stress in db/db mice. PLoS One
2012; 7: e50412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3511555</ArticleId>
            <ArticleId IdType="pubmed">23226280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee E, Ryu GR, Ko SH, et al
Antioxidant treatment may protect pancreatic beta cells through the attenuation of islet fibrosis in an animal model of type 2 diabetes. Biochem Biophys Res Commun
2011; 414: 397–402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21971557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ryu GR, Lee E, Chun HJ, et al
Oxidative stress plays a role in high glucose‐induced activation of pancreatic stellate cells. Biochem Biophys Res Commun
2013; 439: 258–263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23973482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Witteck L, Jaster R. Trametinib and dactolisib but not regorafenib exert antiproliferative effects on rat pancreatic stellate cells. Hepatobiliary Pancreat Dis Int
2015; 14: 642–650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26663013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee E, Ryu GR, Ko SH, et al
A role of pancreatic stellate cells in islet fibrosis and beta‐cell dysfunction in type 2 diabetes mellitus. Biochem Biophys Res Commun
2017; 485: 328–334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28232184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Frantz ED, Crespo‐Mascarenhas C, Barreto‐Vianna AR, et al
Renin‐angiotensin system blockers protect pancreatic islets against diet‐induced obesity and insulin resistance in mice. PLoS One
2013; 8: e67192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3718820</ArticleId>
            <ArticleId IdType="pubmed">23894285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Santos RA, Simoes e Silva AC, Maric C, et al
Angiotensin‐(1–7) is an endogenous ligand for the G protein‐coupled receptor Mas. Proc Natl Acad Sci USA
2003; 100: 8258–8263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC166216</ArticleId>
            <ArticleId IdType="pubmed">12829792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Giani JF, Mayer MA, Munoz MC, et al
Chronic infusion of angiotensin‐(1–7) improves insulin resistance and hypertension induced by a high‐fructose diet in rats. Am J Physiol Endocrinol Metab
2009; 296: E262–271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19001546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pfeffer MA, Swedberg K, Granger CB, et al
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM‐Overall programme. Lancet
2003; 362: 759–766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13678868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Braunwald E, Domanski MJ, Fowler SE, et al
Angiotensin‐converting‐enzyme inhibition in stable coronary artery disease. N Engl J Med
2004; 351: 2058–2068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2556374</ArticleId>
            <ArticleId IdType="pubmed">15531767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yusuf S, Teo KK, Pogue J, et al
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med
2008; 358: 1547–1559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18378520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ogihara T, Ueshima K, Nakao K, et al
Long‐term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high‐risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE‐J Ex). Hypertens Res
2011; 34: 1295–1301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21833000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wing LM, Reid CM, Ryan P, et al
A comparison of outcomes with angiotensin‐converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med
2003; 348: 583–592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12584366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chowdhury EK, Owen A, Ademi Z, et al
Short‐ and long‐term survival in treated elderly hypertensive patients with or without diabetes: findings from the Second Australian National Blood Pressure study. Am J Hypertens
2014; 27: 199–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24249722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
van Westerloo DJ, Florquin S, de Boer AM, et al
Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. Am J Pathol
2005; 166: 721–728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1602356</ArticleId>
            <ArticleId IdType="pubmed">15743784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee BJ, Lee HS, Kim CD, et al
The effects of combined treatment with an HMG‐CoA reductase inhibitor and PPARgamma agonist on the activation of rat pancreatic stellate cells. Gut Liv
2012; 6: 262–269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3343167</ArticleId>
            <ArticleId IdType="pubmed">22570758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shirahige A, Mizushima T, Matsushita K, et al
Oral administration of taurine improves experimental pancreatic fibrosis. J Gastroenterol Hepatol
2008; 23: 321–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17764527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Matsushita K, Mizushima T, Shirahige A, et al
Effect of taurine on acinar cell apoptosis and pancreatic fibrosis in dibutyltin dichloride‐induced chronic pancreatitis. Acta Med Okayama
2012; 66: 329–334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22918205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ohashi S, Nishio A, Nakamura H, et al
Overexpression of redox‐active protein thioredoxin‐1 prevents development of chronic pancreatitis in mice. Antioxid Redox Signal
2006; 8: 1835–1845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16987036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lin Z, Zheng LC, Zhang HJ, et al
Anti‐fibrotic effects of phenolic compounds on pancreatic stellate cells. BMC Complement Altern Med
2015; 15: 259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4520255</ArticleId>
            <ArticleId IdType="pubmed">26223780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sun XD, Liu XE, Huang DS. Curcumin reverses the epithelial‐mesenchymal transition of pancreatic cancer cells by inhibiting the Hedgehog signaling pathway. Oncol Rep
2013; 29: 2401–2407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23563640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asaumi H, Watanabe S, Taguchi M, et al
Green tea polyphenol (‐)‐epigallocatechin‐3‐gallate inhibits ethanol‐induced activation of pancreatic stellate cells. Eur J Clin Investig
2006; 36: 113–122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16436093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rickmann M, Vaquero EC, Malagelada JR, et al
Tocotrienols induce apoptosis and autophagy in rat pancreatic stellate cells through the mitochondrial death pathway. Gastroenterology
2007; 132: 2518–2532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17570223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
McCarroll JA, Phillips PA, Santucci N, et al
Vitamin A inhibits pancreatic stellate cell activation: implications for treatment of pancreatic fibrosis. Gut
2006; 55: 79–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1856372</ArticleId>
            <ArticleId IdType="pubmed">16043492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Guan J, Zhang H, Wen Z, et al
Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL‐6 in cancer associated fibroblast cells. Cancer Lett
2014; 345: 132–139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24334138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xiao W, Jiang W, Shen J, et al
Retinoic acid ameliorates pancreatic fibrosis and inhibits the activation of pancreatic stellate cells in mice with experimental chronic pancreatitis via suppressing the Wnt/beta‐catenin signaling pathway. PLoS One
2015; 10: e0141462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4640570</ArticleId>
            <ArticleId IdType="pubmed">26556479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gonzalez AM, Garcia T, Samper E, et al
Assessment of the protective effects of oral tocotrienols in arginine chronic‐like pancreatitis. Am J Physiol Gastrointest Liver Physiol
2011; 301: G846–G855.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21852363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li XC, Lu XL, Chen HH. alpha‐Tocopherol treatment ameliorates chronic pancreatitis in an experimental rat model induced by trinitrobenzene sulfonic acid. Pancreatology
2011; 11: 5–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21311207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yamada T, Kuno A, Ogawa K, et al
Combination therapy with an angiotensin‐converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats. J Pharmacol Exp Ther
2005; 313: 36–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15608084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yamada T, Kuno A, Masuda K, et al
Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats. J Pharmacol Exp Ther
2003; 307: 17–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12944495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kuno A, Yamada T, Masuda K, et al
Angiotensin‐converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology
2003; 124: 1010–1019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12671898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chauhan VP, Martin JD, Liu H, et al
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun
2013; 4: 2516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3806395</ArticleId>
            <ArticleId IdType="pubmed">24084631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kozono S, Ohuchida K, Eguchi D, et al
Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res
2013; 73: 2345–2356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23348422</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
